Introduction {#Sec1}
============

Medical care has greatly advanced over the last three decades. However; heart failure remains a major cause of morbidity and mortality, with a general prevalence rate of approximately 2% and an abrupt rise to 9% in those aged ≥ 65 years \[[@CR1]\].

Additionally, the prevalence of heart failure is increasing due to an increase in cardiovascular risk factors and increased life expectancy \[[@CR2]\].

Established cardiovascular biomarkers include N-terminal pro-brain natriuretic peptide (NT-proBNP) \[[@CR3]\] and troponin \[[@CR4]\], while emerging biomarkers include miRNAs \[[@CR5]\], mimecan \[[@CR6]\], and orexin \[[@CR7]\]. However, none of these biomarkers are routinely measured, indicating the need for new feasible and reproducible biomarkers that help in screening the functional severity in heart failure patients with reduced ejection fraction (HFrEF).

Consequently, research is still continuing to improve risk stratification tools for cardiovascular disease (CVD), including those specific for chronic heart failure.

Multiple theories have attempted to explain the cardiovascular-hepatic relationship that has been documented with abnormal liver function test results in patients with CVD, including heart failure \[[@CR8]\], ischemic heart disease \[[@CR9]\], and atherosclerosis \[[@CR10]\].

Hepatic fibrosis is no longer considered an isolated hepatic disease on the basis of its association with multisystem dysfunction, including CVD \[[@CR11]\]. Non-invasive indices were developed for early detection and monitoring of hepatic fibrosis \[[@CR12]\]. The validated indices include the Aspartate aminotransferase (AST)/Alanine aminotransferase (ALT) ratio \[[@CR13]\], AST to platelet ratio index (APRI) \[[@CR14]\], Fibrosis-4 score (FIB-4) \[[@CR15]\], and non-alcoholic fatty liver disease (NAFLD) fibrosis score \[[@CR16]\].

Previous reports highlighted the value of non-invasive hepatic fibrosis indices as prognostic tools in hepatic patients \[[@CR17]\]. However, there is little research evaluating these indices in HFrEF patients.

In our study, we have focused on the role of AST/ALT ratio in predicting the functional severity of HFrEF.

Main text {#Sec2}
=========

Methods {#Sec3}
-------

### Study design and participants {#Sec4}

This retrospective cross-sectional study included 105 patients recruited from the heart failure outpatient clinic of Prince Sultan Cardiac Center Qassim (PSCCQ), Buraidah, Saudi Arabia.

All recruited patients had HFrEF according to American College of Cardiology heart failure diagnostic criteria, evidenced by left ventricular ejection fraction (LVEF) ≤ 40% \[[@CR18]\]; we excluded those with any of the following: primary liver disease, sepsis, shock, malignancy, pregnancy, or renal failure.

### Demographic data {#Sec5}

The following variables were collected: age, sex, duration of heart failure, and cardiovascular risk factors including; obesity, diabetes mellitus, smoking, and hypertension.

### Laboratory investigations and calculation of liver fibrosis indices {#Sec6}

Complete blood count, liver function tests, kidney function tests, thyroid profile, and NT-proBNP levels were recorded.

We calculated the following standard non-invasive hepatic fibrosis indices:AST/ALT ratio \[[@CR13]\].AST to platelet ratio index (APRI) \[[@CR14]\] = (\[AST/top normal AST\]/platelet count \[10^9^ /liter\]) × 100.Fibrosis-4 (FIB-4) \[[@CR15]\] = (Age × AST)/(Platelet count × ALT square root).

### Transthoracic echocardiography {#Sec7}

Transthoracic echocardiography was performed according to the recommendations of both the American Society of Echocardiography and European Association of Cardiovascular Imaging.

The modified Simpson's rule was used to estimate left ventricular (LV) volumes and measure the ejection fraction \[[@CR19]\].

### Estimation of systolic pulmonary arterial pressure (SPAP) {#Sec8}

SPAP was estimated using the modified Bernoulli formula (SPAP \[mmHg\] = 4 × tricuspid regurgitation velocity^2^ + right atrial pressure) \[[@CR20]\].

### Classification of patients according to the AST/ALT ratio {#Sec9}

Based on literature review, an AST/ALT ratio ≥ 1 is highly specific and predictive of liver cirrhosis in patients with chronic HCV infection \[[@CR13]\]; we used the same cut-off value to classify our patients into two groups:Group-1: AST/ALT ratio \< 1.0Group-2: AST/ALT ratio ≥ 1.0

We adopted patients' laboratory values, New York Heart Association (NYHA) functional Class and LVEF measurements that were performed after their first interview in the outpatient clinic.

### Statistical methods {#Sec10}

The statistical package MedCalc version 19.0.5 was used for all statistical analyses. Quantitative data are presented as mean ± standard deviation, and qualitative data are presented as percentages. Comparisons between groups were made using the Mann--Whitney test. Correlations between variables were analyzed using Spearman's rank correlation coefficient. Multivariate linear regression was used to investigate the independent predictability of AST/ALT ratio for LVEF percentage \[LVEF (%)\].

Results {#Sec11}
=======

This study included 105 patients (50 ± 14.71, 16--88 years; 68 men). Both study groups showed comparable results; however, Group-2 showed a less favorable cardiac profile. NYHA class and NT-proBNP were higher and LVEF was lower in group-2 than in group-1 (Table [1](#Tab1){ref-type="table"}).Table 1Descriptive data of subjects with AST/ALT ratio \< 1 and ≥ 1ParameterGroup-1 (58 patients) \[AST/ALT ratio \< 1\]Group-2 (47 patients) \[AST/ALT ratio ≥ 1\]P-valueAge (year)50.03 ± 15.25 (16--82)50.17 ± 14.18 (21--88)0.915Gender (n, %)44 males (75%)24 males (51%)0.009Heart failure Duration (year)5.43 ± 2.46 (2--12)4.55 ± 3.09 (1--13)0.021NYHA--class2.12 ± 1.04 (1--4)2.49 ± 0.86 (1--4)0.042Diabetes mellitus (n, %)37 (63.8%)26 (55.32%)0.052Hypertension (n, %)33 (56.9%)25 (53.2%)0.632Smoking (n, %)10 (17.24%)11(23.4%)0.493BMI (kg/m^2^)28.72 ± 5.8 (16--40)30.33 ± 9.42 (17.6--70)0.609Systolic BP (mmHg)123.19 ± 20.19 (90--185)127.02 ± 17.5 (100--171)0.248Diastolic BP (mmHg)73 ± 11.57 (52--99)73.68 ± 10.63 (50--111)0.701Hemoglobin (g/dL)13.65 ± 1.76 (9.2--17.7)12.86 ± 2.18 (7.5--16.3)0.086Platelets (× 10^9^/L)267.68 ± 72.25 (137--422)299.71 ± 94.94 (149--588)0.180Fasting blood sugar (mmol/L)15.62 ± 27.62 (4.38--140)10.24 ± 6.44 (4.82--24.8)0.874Potassium^+^ (mEq/L)4.2 ± 0.52 (3.1--5.8)4.1 ± 0.58 (2.8--5.7)0.415Sodium^+^ (mEq/L)136.96 ± 4.43 (127--146)135.98 ± 3.83 (127--143)0.261Serum creatinine (mmol/L)109.57 ± 80.95 (50--581)114.86 ± 97.72 (57--538)0.741Blood urea (mmol/L)7 ± 3.36 (2.7--19)7.34 ± 5.27 (2.8--30.6)0.588Total cholesterol (mmol/L)3.99 ± 1.13 (1.06--5.86)4.35 ± 1.64 (1.2--7.8)0.373HDL cholesterol (mmol/L)0.93 ± 0.25 (0.53--1.39)0.99 ± 0.35 (0.25--1.68)0.459Triglycerides (mmol/L)2.08 ± 1.36 (0.51--6.36)1.57 ± 0.99 (0.64--4.94)0.068T3 (nmol/L)5.25 ± 2.75 (1.11--16.95)6.87 ± 4.78 (4.07--17.67)0.655T4 (nmol/L)13.64 ± 5.15 (1.62--20.7)13.75 ± 4.46 (3.71--19.99)0.981TSH (mIU/L)9.15 ± 32.54 (1--193)6.6 ± 10.05 (0.19--48)0.899Bilirubin (mg/dL)11.88 ± 11.63 (3--67.9)12.75 ± 12.2 (0.7--64)0.722Albumin (g/dL)36.02 ± 4.51 (24.2--45.4)33.68 ± 8.61 (38--44.2)0.492aPTT (s)38.08 ± 20.72 (16--126)35.38 ± 13.57 (18--84.3)0.549INR1.15 ± 0.15 (1--1.6)1.22 ± 47 (0.94--3.7)0.737AST (IU/L)32.03 ± 50.31 (10--351)75.17 ± 163.59 (7--763)0.195ALT (IU/L)52.05 ± 71.05 (15--520)25.57 ± 24.37 (4--121)0.001GGT (U/L)89.67 ± 101.8 (6--203)25.48 ± 19.33 (6--52)0.479ALP (U/L)102.38 ± 57.81 (48--385)98.89 ± 53.14 (34--276)0.449AST/ALT ratio0.63 ± 0.19 (0.16--0.94)1.3 ± 0.25 (0.95--1.85)0.001APRI index0.31 ± 0.41 (0.09--2.8)0.74 ± 1.76 (0.07--8.03)0.877FIB-4 score0.8 ± 0.43 (0.17--1.96)1.1 ± 0.81 (0.3--3.6)0.002NT-proBNP (pg/mL)1212.9 ± 1869.2 (8.4--8455)1845.6 ± 2271.8 (4.1--9595)0.089LVEF (%)28.93 ± 10.26 (16--43)23.83 ± 7.04 (14--36)0.012SPAP (mmHg)42.33 ± 19.03 (15--63)45.25 ± 13.34 (22--70)0.344

The results showed a mild significant correlation between the AST/ALT ratio and the following variables: APRI, FIB-4 score, NYHA-class, and LVEF (r = 0.2, 0.25, 0.26, and − 0.24;P \< 0.05) respectively.

Additionally, LVEF had significant correlations (− 0.26, − 0.46, − 0.29, − 0.25; P \< 0.05) with NYHA-class, left ventricular end systolic pressure, SPAP, and NT-proBNP, respectively.

The receiver operating characteristic (ROC) curve showed that the ASL/ALT ratio could predict the functional severity of LV systolic failure measured by LVEF. We used the American Society of Echocardiography cut-off value (LVEF \< 30%) for diagnosing patients with severely impaired LVEF \[[@CR19]\]. The area under the curve (AUC) was 0.64 (P \< 0.05) with a 95% confidence interval of 0.54--0.73 with a best cut-off value of 0.9, sensitivity of 43.6%, and specificity of 81.4% (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1AROC-curve showing ALT/AST ratio prediction of reduced LVEF

In our multivariate linear regression model that included age, body mass index (BMI), diabetes mellitus, hypertension, and NT-proBNP, the AST/ALT ratio was a significant independent predictor of LVEF% (95% confidence interval, 0.85--1.01; P \< 0.05, Table [2](#Tab2){ref-type="table"}).Table 2Multivariate linear regression model for prediction of LVEF(%)ParametersStandardized coefficient95% CIP-valueAge− 0.17447.25--52.940.102BMI0.06127.80--30.990.696Diabetes mellitus0.4331.56--1.750.879Hypertension1.9031.46--1.660.502AST/ALT ratio− 6.7960.85--1.010.045NT-proBNP− 0.001932.91--2007.760.195

Discussion {#Sec12}
==========

Our main finding in this study is that an increased AST/ALT ratio could predict functional status decline in HFrEF patients, as shown by the less favorable cardiac profile in Group-2.

Moreover, the predictive value of the AST/ALT ratio is independent after adjustment for age, BMI, hypertension, diabetes mellitus, and NT-proBNP.

Our explanation for this main finding is multi-factorial; it is known that AST is released from many tissues, including the myocardium and the liver, while ALT is only released from the liver. Therefore, more severe myocardial pathology would lead to an anticipated increase in the AST/ALT ratio \[[@CR21]\]. Additionally, higher the AST/ALT ratio, greater the probability of hepatic fibrosis, which is associated with cardiovascular disease (CVD) pathogenesis through different mechanisms, including increased plasma inflammatory mediators, insulin resistance, oxidative stress, and metabolic syndrome \[[@CR22]\].

Based on their medical records, our patients did not have any primary hepatic disorders to justify the increased AST/ALT ratio. It is known that an increased AST/ALT ratio is also caused by alcoholic liver disease \[[@CR23]\]. However, our records did not include those with alcohol drinking habits.

Hypoxic hepatitis is another cause of increased AST/ALT ratio in its early phase; however, our data showed that ALT and AST values were far less than those required for diagnosing classic hypoxic hepatitis \[[@CR24]\].

Previous research has focused on the value of hepatic transaminases as CVD predictors. Lazo et al. \[[@CR25]\] showed that elevated levels of liver transaminases were significantly correlated with the cardiac biomarkers; troponin T and NT-proBNP. Consequently, they concluded that liver transaminases could be used as predictors in patients at risk of CVD. However, they did not enroll heart failure patients in their study, as they were only concerned with predicting subclinical myocardial injury.

Yokoyama et al. \[[@CR26]\] recently concluded that an increased AST/ALT ratio positively correlates with NT-proBNP levels, yet their study was not specific for HFrEF patients.

Zoppini et al. \[[@CR27]\] studied patients with type 2 diabetes mellitus and found that the AST/ALT ratio positively correlated with CVD mortality; however, as in the above studies, they did not include HFrEF patients.

On the other hand, there are some studies that did not show significant correlation between ALT and CVD, as seen by both Ruhl et al. \[[@CR28]\] and Fraser et al. \[[@CR29]\] However, they did not include AST or the AST/ALT ratio in their correlations with CVD, which could be an explanation for the non-significant result.

In our study, we found that 0.9 was the best predictive cut-off value of the AST/ALT ratio when considering functional severity in HFrEF patients. Our finding was in agreement with the finding of Long et al. \[[@CR30]\] that 1 was the best cut-off value of the AST/ALT ratio that predicted cardio-metabolic risk in their study.

To our knowledge, our study is the first in Saudi Arabia and other Arabian countries to correlate the AST/ALT ratio with functional severity in HFrEF patients. Consequently, we could not find comparable AST/ALT cut-off values in the Arab population.

Our cut-off value could be very helpful in monitoring the functional status of HFrEF patients in primary healthcare settings and accordingly adjusting their follow-up investigations/management plans.

Conclusion {#Sec13}
==========

Our study highlighted the value of the AST/ALT ratio as a simple independent predictor of LV functional status in patients with HFrEF.

Recommendation {#Sec14}
==============

Based on our findings, we recommend future prospective studies to establish the potential practical value of AST/ALT ratio in monitoring the functional status of patients with HFrEF.

Limitations {#Sec15}
===========

Our study had some limitations, including its retrospective nature; accordingly, we could not follow-up with the patients for detailed morbidity and mortality records in relation to AST/ALT ratio measurements. In addition, our study was a single-center study and prospective multicenter studies could improve our understanding regarding the correlation of AST/ALT ratio with HFrEF functional status.
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